NICE TA260: Botulinum toxin type A (Botox) for the prevention of headaches in adults with chronic migraine. (Decision date - July 2012).
NICE TA605: Botulinum neurotoxin type A (Xeomin) recommended for treating chronic sialorrhoea. (Decision date - November 2019).
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)